Jerusalem Pharmaceuticals Co. Ltd. (PEX:JPH)
Palestine
· Delayed Price · Currency is JOD · Price in USD 4.650
0.00 (0.00%)
At close: Mar 4, 2026
Jerusalem Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 49.93 | 39.82 | 39.65 | 46.14 | 46.23 | Upgrade
|
| Revenue Growth (YoY) | 25.39% | 0.42% | -14.06% | -0.18% | 27.00% | Upgrade
|
| Cost of Revenue | 22.56 | 19.7 | 18.31 | 23 | 23.44 | Upgrade
|
| Gross Profit | 27.37 | 20.12 | 21.34 | 23.14 | 22.79 | Upgrade
|
| Selling, General & Admin | 12.42 | 10.52 | 10.77 | 12.23 | 12.57 | Upgrade
|
| Research & Development | 1.4 | 1.12 | 0.93 | 1.73 | 1.74 | Upgrade
|
| Other Operating Expenses | -0.14 | -0.09 | -0.15 | -0.26 | 0.07 | Upgrade
|
| Operating Expenses | 14.47 | 13.42 | 12.36 | 14.33 | 14.81 | Upgrade
|
| Operating Income | 12.89 | 6.7 | 8.98 | 8.81 | 7.98 | Upgrade
|
| Interest Expense | -0.28 | -0.02 | -0.04 | -0.06 | -0.06 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.03 | 0.02 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -0 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.17 | -0.64 | -0.08 | 0.36 | -0.21 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -0.29 | -0.19 | -0.14 | -0.16 | Upgrade
|
| EBT Excluding Unusual Items | 11.44 | 5.76 | 8.68 | 9 | 7.57 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.59 | 0.84 | 0.04 | 0 | 0 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0 | 0.11 | - | 0.01 | Upgrade
|
| Other Unusual Items | - | 0.02 | - | 0.03 | 0.04 | Upgrade
|
| Pretax Income | 13.03 | 6.62 | 8.82 | 9.03 | 7.62 | Upgrade
|
| Income Tax Expense | 2.72 | 1.56 | 1.81 | 1.82 | 1.4 | Upgrade
|
| Earnings From Continuing Operations | 10.31 | 5.06 | 7.01 | 7.21 | 6.22 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | -0.21 | - | Upgrade
|
| Net Income to Company | 10.31 | 5.06 | 7.01 | 7 | 6.22 | Upgrade
|
| Minority Interest in Earnings | -0.07 | -0.02 | -0.05 | 0.17 | 0.38 | Upgrade
|
| Net Income | 10.23 | 5.04 | 6.96 | 7.17 | 6.6 | Upgrade
|
| Net Income to Common | 10.23 | 5.04 | 6.96 | 7.17 | 6.6 | Upgrade
|
| Net Income Growth | 103.10% | -27.58% | -3.02% | 8.73% | 77.11% | Upgrade
|
| Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | 0.08% | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.57 | 0.28 | 0.39 | 0.40 | 0.37 | Upgrade
|
| EPS (Diluted) | 0.57 | 0.28 | 0.39 | 0.40 | 0.37 | Upgrade
|
| EPS Growth | 102.94% | -27.58% | -3.02% | 8.73% | 77.11% | Upgrade
|
| Free Cash Flow | 1.48 | 9.94 | 7.84 | 16.32 | 3.86 | Upgrade
|
| Free Cash Flow Per Share | 0.08 | 0.55 | 0.44 | 0.91 | 0.21 | Upgrade
|
| Dividend Per Share | - | 0.080 | 0.100 | 0.150 | 0.120 | Upgrade
|
| Dividend Growth | - | -20.00% | -33.33% | 25.00% | 50.00% | Upgrade
|
| Gross Margin | 54.81% | 50.52% | 53.82% | 50.15% | 49.30% | Upgrade
|
| Operating Margin | 25.82% | 16.83% | 22.65% | 19.09% | 17.25% | Upgrade
|
| Profit Margin | 20.49% | 12.65% | 17.54% | 15.55% | 14.27% | Upgrade
|
| Free Cash Flow Margin | 2.97% | 24.96% | 19.77% | 35.37% | 8.35% | Upgrade
|
| EBITDA | 14.77 | 7.95 | 10.17 | 10.53 | 9.94 | Upgrade
|
| EBITDA Margin | 29.57% | 19.95% | 25.65% | 22.83% | 21.50% | Upgrade
|
| D&A For EBITDA | 1.87 | 1.24 | 1.19 | 1.73 | 1.96 | Upgrade
|
| EBIT | 12.89 | 6.7 | 8.98 | 8.81 | 7.98 | Upgrade
|
| EBIT Margin | 25.82% | 16.83% | 22.65% | 19.09% | 17.25% | Upgrade
|
| Effective Tax Rate | 20.90% | 23.52% | 20.55% | 20.18% | 18.42% | Upgrade
|
| Advertising Expenses | - | 0.02 | 0.01 | 0.06 | 0.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.